- Home
- CPAY vs BIIB Comparison
CPAY vs BIIB Comparison
Compare CPAY & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPAY
- BIIB
- Stock Information
- Founded
- CPAY 1986
- BIIB 1978
- Country
- CPAY United States
- BIIB United States
- Employees
- CPAY N/A
- BIIB N/A
- Industry
- CPAY EDP Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- CPAY Technology
- BIIB Health Care
- Exchange
- CPAY Nasdaq
- BIIB Nasdaq
- Market Cap
- CPAY 24.1B
- BIIB 25.1B
- IPO Year
- CPAY 2010
- BIIB 1991
- Fundamental
- Price
- CPAY $343.90
- BIIB $146.47
- Analyst Decision
- CPAY Buy
- BIIB Buy
- Analyst Count
- CPAY 12
- BIIB 26
- Target Price
- CPAY $383.55
- BIIB $248.00
- AVG Volume (30 Days)
- CPAY 447.1K
- BIIB 1.7M
- Earning Date
- CPAY 02-05-2025
- BIIB 02-11-2025
- Dividend Yield
- CPAY N/A
- BIIB N/A
- EPS Growth
- CPAY 9.84
- BIIB 10.05
- EPS
- CPAY 14.01
- BIIB 11.06
- Revenue
- CPAY $3,877,478,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- CPAY $8.44
- BIIB N/A
- Revenue Next Year
- CPAY $11.83
- BIIB N/A
- P/E Ratio
- CPAY $24.54
- BIIB $13.24
- Revenue Growth
- CPAY 4.68
- BIIB N/A
- 52 Week Low
- CPAY $247.10
- BIIB $145.07
- 52 Week High
- CPAY $385.30
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- CPAY 37.19
- BIIB 24.17
- Support Level
- CPAY $356.09
- BIIB $148.60
- Resistance Level
- CPAY $368.10
- BIIB $154.24
- Average True Range (ATR)
- CPAY 7.70
- BIIB 3.71
- MACD
- CPAY -4.22
- BIIB -0.37
- Stochastic Oscillator
- CPAY 19.49
- BIIB 7.48
About CPAY Corpay Inc.
Corpay Inc is a global S&P500 corporate payments company that helps businesses and consumers pay expenses in a simple, controlled manner. Its suite of modern payment solutions helps its customers better manage vehicle-related expenses (such as fueling and parking), travel expenses (e.g. hotel bookings), and payables (e.g. paying vendors). This results in its customers saving time and ultimately spending less.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.